Oral antidiabetic medications - Sulfonylureas and meglitinides: Nursing pharmacology

1,218views

Oral antidiabetic medications - Sulfonylureas and meglitinides: Nursing pharmacology

nancy

nancy

Pharmacokinetics - Absorption: Nursing pharmacology
Medication administration - Safety principles: Nursing pharmacology
Pharmacokinetics - Elimination: Nursing pharmacology
Pharmacokinetics - Distribution: Nursing pharmacology
Pharmacokinetics - Metabolism: Nursing pharmacology
Care of a client identifying as LGBTQ+: Nursing
Health and illness models: Nursing
Core measures: Nursing
Public health nursing: Nursing
Healthcare costs: Nursing
Health promotion and illness prevention: Nursing
Antacids: Nursing pharmacology
Antidiarrheals: Nursing pharmacology
Antiemetics: Nursing pharmacology
Antispasmodics (GI): Nursing pharmacology
Gallstone-dissolving agents: Nursing pharmacology
Gastric mucosal protective agents: Nursing pharmacology
Histamine H2 antagonists: Nursing pharmacology
Laxatives: Nursing pharmacology
Medications for hepatic encephalopathy: Nursing pharmacology
Pancreatic enzyme replacements: Nursing pharmacology
Proton pump inhibitors (PPIs): Nursing pharmacology
Treatment for Helicobacter pylori: Nursing pharmacology
Weight loss medications: Nursing pharmacology
Physiology of pain: Nursing
Pain
Vital signs - Pain: Nursing skills
Alpha-1 adrenergic blockers: Nursing pharmacology
Alpha-2 adrenergic agonists: Nursing pharmacology
Angiotensin II receptor blockers (ARBs): Nursing pharmacology
Angiotensin-converting enzyme (ACE) inhibitors: Nursing pharmacology
Antiarrhythmics: Nursing pharmacology
Anticoagulants - Direct thrombin and factor Xa inhibitors: Nursing pharmacology
Anticoagulants - Heparin: Nursing pharmacology
Anticoagulants - Warfarin: Nursing pharmacology
Antihyperlipidemics - Bile acid sequestrants and cholesterol absorption inhibitors: Nursing pharmacology
Antihyperlipidemics - Fibrates: Nursing pharmacology
Antihyperlipidemics - Miscellaneous: Nursing pharmacology
Antihyperlipidemics - Statins: Nursing pharmacology
Antiplatelet agents: Nursing pharmacology
Beta-adrenergic blockers: Nursing pharmacology
Calcium-channel blockers: Nursing pharmacology
Cardiac glycosides: Nursing pharmacology
Cholinergic therapy - Overview: Nursing pharmacology
Direct-acting vasodilators: Nursing pharmacology
Diuretics - Osmotic and carbonic anhydrase inhibitors: Nursing pharmacology
Diuretics - Thiazide, thiazide-like, loop, and potassium-sparing diuretics: Nursing pharmacology
Nitrates: Nursing pharmacology
Sympathomimetic medications: Nursing pharmacology
Amblyopia: Nursing
Cataracts: Nursing
Detached retina: Nursing
Hearing impairment and otosclerosis: Nursing
Legal blindness: Nursing
Macular degeneration: Nursing
Meniere disease: Nursing
Pharyngitis: Nursing
Retinoblastoma: Nursing
Strabismus: Nursing
Evidence-based practice (EBP): Nursing
Antiglaucoma medications: Nursing pharmacology
Acne: Nursing
Medications for acne vulgaris: Nursing pharmacology
Insulin: Nursing pharmacology
Oral antidiabetic medications - Alpha-glucosidase inhibitors: Nursing pharmacology
Oral antidiabetic medications - DPP-4 inhibitors: Nursing pharmacology
Oral antidiabetic medications - Sulfonylureas and meglitinides: Nursing pharmacology
Oral antidiabetic medications - Sodium-glucose co-transporter-2 (SGLT-2) inhibitors: Nursing pharmacology
Non-insulin injectable antidiabetic drugs - GLP-1 agonists and amylinomimetics: Nursing pharmacology
Oral antidiabetic medications - Biguanides and thiazolidinediones: Nursing pharmacology
Antipsychotics: Nursing pharmacology
Grief and loss: Nursing
Stress and coping: Nursing

Notes

SULFONYLUREAS & MEGLITINIDES
DRUG NAME
glimepiride (Amaryl), glipizide (Glucotrol), glyburide (Glynase)
*High Alert Medications*

repaglinide, nateglinide
*High Alert Medications*

CLASS
Sulfonylureas
Meglitinides
MECHANISM OF ACTION
Inhibit ATP-sensitive K+ channels on pancreatic beta cells → increase insulin secretion → decrease blood glucose levels
INDICATIONS
Type 2 diabetes mellitus
ROUTE(S) OF ADMINISTRATION
PO
SIDE EFFECTS
  • Hypoglycemia
  • Hepatotoxicity
  • Leukopenia
  • Thrombocytopenia
  • Weight gain
CONTRAINDICATIONS AND CAUTIONS
  • Type 1 diabetes mellitus
  • Diabetic ketoacidosis (DKA)
  • Pregnancy and breastfeeding
  • Children or elderly clients
  • Hepatic or renal disease
NURSING CONSIDERATIONS: SULFONYLUREAS & MEGLITINIDES
ASSESSMENT AND MONITORING
Sulfonylureas and meglitinides
Assess
  • Laboratory test results, including CBC, blood glucose, hemoglobin A1c, electrolytes, renal and hepatic function
Monitor
  • Side effects and therapeutic response: blood glucose, hemoglobin A1c levels, CBC, liver and renal function tests
CLIENT EDUCATION
Sulfonylureas and meglitinides
  • Purpose of medication: lowers blood glucose levels by increasing insulin release from pancreas
  • Continue antidiabetic regimen: low-carbohydrate and high-fiber diet, regular physical activity, frequent blood glucose monitoring
  • Timing of medication administration with meals
    • Glipizide: take 30 minutes before the first meal of the day
    • Repaglinide: take within 30 minutes of each meal; do not take if a meal is skipped
  • Recognize hyperglycemia: fatigue, blurred vision; increased thirst, appetite, and urination
    • Check glucose level
    • Contact healthcare provider
  • Recognize hypoglycemia: hunger, headache, fatigue, tremors, dizziness, confusion
    • Check blood glucose level
    • Consume a source of glucose; e.g., half a cup of orange juice, three glucose tablets, or approximately 15 grams of sugar
    • Check blood glucose after 15 minutes
  • Avoid alcohol (sulfonylureas)
    • Increases hypoglycemic effect
    • Disulfiram-like reaction: flushing, palpitations, nausea
      • Contact HCP
Author: Maria Emfietzoglou, MD
Illustrator: Robyn Hughes, MScBMC

Transcript

Watch video only

Sulfonylureas and meglitinides are medications used to treat type 2 diabetes mellitus. Type 2 diabetes is characterized by insulin resistance, which is when tissue cells have trouble responding to insulin in order to use glucose from the blood. As a result, tissue cells starve for energy despite having high blood glucose levels, which is called hyperglycemia.

Now, sulfonylureas can be classified into first and second generation and are easy to recognize because they all have the suffix “–ide” and include glimepiride, glipizide and glyburide. On the other hand, meglitinides have the suffix “-glinide” and include repaglinide and nateglinide.

Okay, now both sulfonylureas and meglitinides are given orally and once administered, they both act on the pancreas by inhibiting ATP-sensitive potassium channels on the membrane of pancreatic beta cells. As a result, these medications initiate a cascade of events that stimulate the pancreatic beta cells to secrete more insulin, ultimately leading to a decrease in blood glucose levels.

The most common side effects of both classes of medications are hypoglycemia and weight gain. Other notable side effects of sulfonylureas include hepatotoxicity, leukopenia, and thrombocytopenia; while meglitinides commonly cause nausea, diarrhea, and indigestion.

As far as contraindications go, both sulfonylureas and meglitinides should not be used in clients with type 1 diabetes mellitus, or those experiencing diabetic ketoacidosis or DKA, since these medications will be ineffective in patients with no pancreatic beta-cell function. In addition, some of these medications should be used with caution during pregnancy and breastfeeding, as well as in children or elderly clients. Final precautions for these medications include hepatic or renal disease.

Alright, if a client with type 2 diabetes is prescribed an oral antidiabetic medication, such as a sulfonylurea or meglitinide, be sure to review their most recent laboratory test results, including blood glucose, hemoglobin A1c, CBC, electrolytes, as well as their renal and hepatic function. Next, explain how the medication works in their pancreas to lower their blood glucose level. Be sure to remind your client that the medication is most effective when combined with an antidiabetic regimen, which includes following a low-carbohydrate and high-fiber diet, regular physical activity, and frequent blood glucose monitoring.

Next, review with your client the symptoms of hyperglycemia, such as fatigue, blurred vision, increased thirst, appetite, and urination; if the client develops any of these symptoms, advise them to check their blood glucose level and contact their healthcare provider immediately. Then, review the symptoms of hypoglycemia, such as hunger, headache, fatigue, tremors, dizziness, and confusion; if the client develops any of these, instruct them to check blood glucose level, followed by consuming a source of glucose, such as half a cup of juice, three glucose tablets, or approximately 15 grams of sugar; and then check blood glucose again after 15 minutes.

Okay, if your client is prescribed the sulfonylurea “glipizide,” teach them to take their medication once daily, 30 minutes before the first meal of the day. Then, let them know that they should avoid consuming alcohol, since it can increase the hypoglycemic effects of glipizide, and may cause a disulfiram-like reaction, characterized by flushing, palpitations, and nausea.

If these occur, stress the importance of contacting their healthcare provider right away.

Sources

  1. "Lehne’s Pharmacology for Nursing Care. 12th edition. ISBN: 978-0-443-10710-8 " Elsevier (2026)
  2. "Karch’s Focus on Nursing Pharmacology (9th edition). ISBN: 978-1-975180-40-9" LWW (2023)
  3. "Pharmacology: A Patient-Centered Nursing Process Approach. 9th edition. ISBN: 978-0-323-39916-6 " Elsevier Canada (2020)
  4. "Lewis’s Medical-Surgical Nursing: Assessment and Management of Clinical Problems. 11th Edition. ISBN: 978-0-323-55149-6 " Mosby (2019)
  5. "Saunders Comprehensive Review for the NCLEX-RN. 9th Edition. ISBN: 978-0-323-79530-2" Saunders (2022)
  6. "Pharmacogenetics of Type 2 Diabetes-Progress and Prospects. 21(18):6842" Int J Mol Sci (2020)
  7. "Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis. 120:154780" Metabolism (2021)